PKO Investment Management Joint Stock Co Has $352,000 Stock Holdings in Biogen Inc. $BIIB

PKO Investment Management Joint Stock Co lowered its position in Biogen Inc. (NASDAQ:BIIB) by 66.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,000 shares of the biotechnology company’s stock after selling 4,000 shares during the period. PKO Investment Management Joint Stock Co’s holdings in Biogen were worth $352,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its position in Biogen by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 17,447,092 shares of the biotechnology company’s stock worth $3,070,514,000 after buying an additional 157,857 shares in the last quarter. Invesco Ltd. raised its holdings in Biogen by 4.2% in the 3rd quarter. Invesco Ltd. now owns 2,418,127 shares of the biotechnology company’s stock valued at $338,731,000 after acquiring an additional 98,001 shares during the period. AQR Capital Management LLC raised its holdings in Biogen by 30.7% in the 3rd quarter. AQR Capital Management LLC now owns 1,783,581 shares of the biotechnology company’s stock valued at $248,809,000 after acquiring an additional 418,776 shares during the period. Legal & General Group Plc increased its holdings in shares of Biogen by 10.1% during the third quarter. Legal & General Group Plc now owns 1,593,399 shares of the biotechnology company’s stock worth $223,203,000 after purchasing an additional 146,583 shares during the period. Finally, Pictet Asset Management Holding SA increased its holdings in shares of Biogen by 22.9% during the fourth quarter. Pictet Asset Management Holding SA now owns 947,494 shares of the biotechnology company’s stock worth $166,900,000 after purchasing an additional 176,639 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the sale, the insider owned 8,043 shares of the company’s stock, valued at $1,607,232.69. This represents a 24.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.18% of the stock is owned by insiders.

Analyst Ratings Changes

Several analysts recently issued reports on the stock. Truist Financial reduced their price target on shares of Biogen from $193.00 to $189.00 and set a “hold” rating on the stock in a research report on Monday, April 13th. HSBC lifted their price target on shares of Biogen from $143.00 to $150.00 and gave the stock a “reduce” rating in a report on Tuesday, March 17th. Canaccord Genuity Group boosted their target price on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. Sanford C. Bernstein dropped their target price on shares of Biogen from $201.00 to $200.00 in a report on Thursday. Finally, Oppenheimer boosted their target price on shares of Biogen from $250.00 to $275.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 1st. Thirteen investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $214.23.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q1 beat driven by growth from newer drugs (Leqembi, Skyclarys) and upbeat revenue/profit metrics that underpin optimism about Biogen’s growth portfolio. Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook
• Positive Sentiment: RBC raised its price target to $222 and maintained an Outperform rating, signaling strong analyst conviction and upside potential for BIIB. RBC raises PT to $222
• Positive Sentiment: H.C. Wainwright reiterated a Buy and lifted its PT to $237, citing reduced risk on BIIB080 (Alzheimer’s) — a bullish signal for upside from pipeline progress. H.C. Wainwright reiterates Buy, PT $237
• Positive Sentiment: TD Cowen initiated / affirmed a Buy with a $215 price target, citing strong Q1, pipeline progress and the Apellis deal as supportive factors. TD Cowen Buy, PT $215
• Positive Sentiment: Rothschild & Co Redburn nudged its PT up to $190 (small upside), reflecting modestly improved near-term views. Rothschild raises PT to $190
• Neutral Sentiment: BMO kept a Market Perform/Hold rating with an unchanged $196 target, signaling that some analysts see constrained near-term growth despite the beat. BMO maintains Hold, PT $196
• Neutral Sentiment: Several analyst notes and commentary highlight mixed takeaways: firms generally raised forecasts after the Q1 beat but some also trimmed FY2026 EPS expectations, producing varied buy/hold calls. Analysts boost forecasts after Q1
• Negative Sentiment: Biogen disclosed the Apellis transaction will create a ~$120M–$130M other‑income headwind in 2026 (non‑GAAP EPS accretion expected in 2027), creating a near‑term earnings drag that pressured sentiment. Apellis deal impact
• Negative Sentiment: Sanford C. Bernstein trimmed its PT slightly from $201 to $200 — a modest negative signal that may contribute to profit-taking amid mixed analyst reactions. Bernstein trims PT to $200

Biogen Stock Performance

Biogen stock opened at $187.06 on Monday. The firm’s 50 day simple moving average is $184.52 and its 200 day simple moving average is $176.50. The firm has a market capitalization of $27.62 billion, a PE ratio of 20.07, a price-to-earnings-growth ratio of 1.53 and a beta of 0.19. Biogen Inc. has a 1-year low of $115.25 and a 1-year high of $202.41. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The firm had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the prior year, the firm earned $3.02 EPS. The business’s revenue for the quarter was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, analysts expect that Biogen Inc. will post 15.24 earnings per share for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.